Fluconazole Safety and Efficacy

Introduction to Fluconazole Therapy

The National Comprehensive Cancer Network recommends monitoring hepatic enzymes before starting fluconazole, at 2 and 4 weeks after initiation, and every 3 months during therapy, due to the risk of liver toxicity 1, 2
Fluconazole is generally well tolerated with serious adverse events being rare, primarily manifesting as liver toxicity 1, 2

Fluconazole may cause QTc prolongation, especially when combined with other medications such as fluoroquinolones, macrolides, or ondansetron 1, 2
Fluconazole inhibits cytochrome P450 enzymes (CYP3A4, CYP2C9, and CYP2C19), potentially causing significant drug-drug interactions 1, 2
The most common serious adverse event associated with fluconazole is liver toxicity, not pancreatitis 1, 2

The British Association of Dermatologists recommends baseline liver function tests before starting fluconazole therapy, particularly for patients receiving high-dose or prolonged therapy 3
Current clinical guidelines from the Infectious Diseases Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) do not list pancreatitis as a known adverse effect of fluconazole 1, 2, 4
For patients requiring long-term fluconazole therapy, regular monitoring of liver function is recommended 3
When prescribing long-term fluconazole, clinicians should be vigilant for potential drug-drug interactions, especially with medications metabolized by CYP3A4, CYP2C9, and CYP2C19 enzymes 1, 2